Highlights on a yearly basis1)
|
2021/222) | 2020/212) | 2019/202) | |||
|---|---|---|---|---|---|---|
| €m |
% | €m | % | €m | % | |
| Revenue | 1,902.8 | 100.0 | 1,646.8 | 100.0 | 1,335.5 | 100.0 |
| Research and development expenses | 291.4 | 15.3 | 232.1 | 14.1 | 218.8 | 16.4 |
| EBIT | 396.9 | 20.9 | 373.6 | 22.7 | 177.6 | 13.3 |
| Consolidated profit3) | 295.9 | 15.6 | 237.5 | 14.4 | 123.4 | 9.2 |
| Earnings per share4) (in €) |
3.29 | 2.64 | 1.37 | |||
| Dividend per share (in €) |
1.105) | 0.905) | 0.505) | |||
| Cash flows from operating activities | 188.2 | 362.7 | 178.5 | |||
| Cash flows from investing activities | -148.9 | -75.2 | -70.9 | |||
| Cash flows from financing activities | -38.2 | -285.9 | -123.0 | |||
| Total assets | 2,822.8 | 100.0 | 2,396.0 | 100.0 | 2,014.9 | 100.0 |
| Property, plant and equipment | 236.1 | 8.4 | 199.6 | 8.3 | 135.3 | 6.7 |
| Equity | 2,030.1 | 71.9 | 1,677.4 | 70.0 | 1,450.6 | 72.0 |
| Net liquidity6) | 885.6 | 30.3 | 939.9 | 35.0 | 708.2 | 34.6 |
| Employees at end of reporting periode (30 September) |
4,224 | 3,531 | 3,290 |
|||
1) Ending 30 September
2) Consolidated figures according to IFRS
3) Before non-controlling interests
4) Earnings/(loss) per share attributable to the shareholders of the parent company in the fiscal year
5) Amount proposed by the Supervisory Board and the Management Board of Carl Zeiss Meditec AG
6) Cash and cash equivalents plus treasury receivables from/payables to the treasury of Carl Zeiss AG
